Carbamazepine-induced hyperammonemia

American Journal of Health-System Pharmacy

Volumn 66, Issue 16, 2009, Pages 1468-1470

  Adams, Erin N ^a   Marks, Alla ^a   Lizer, Mitsi H ^a  

^a SHENANDOAH UNIVERSITY   (United States)

Author keywords

Anticonvulsants; Carbamazepine; Desmopressin acetate; Guanfacine; Hyperammonemia; Olanzapine; Quetiapine; Topiramate; Toxicity

Indexed keywords

CARBAMAZEPINE; CARNITINE; DESMOPRESSIN ACETATE; GUANFACINE; LACTULOSE; OLANZAPINE; QUETIAPINE; TOPIRAMATE; TRAZODONE; VALPROIC ACID;

ADULT; AMMONIA BLOOD LEVEL; ANAMNESIS; ARTICLE; BEDTIME DOSAGE; BIPOLAR DISORDER; BRAIN DISEASE; CASE REPORT; CLINICAL FEATURE; COMORBIDITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG LABELING; DRUG MECHANISM; DRUG WITHDRAWAL; HUMAN; HYPERAMMONEMIA; INSOMNIA; MALE; MORNING DOSAGE; OFF LABEL DRUG USE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SEIZURE; TRAUMATIC BRAIN INJURY;

EID: 69249164718     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080454     Document Type: Article

References (23)

1. Tegretol (carbamazepine) package insert. East Hanover, NJ: Novartis; 2008 Apr.
2. Fleminger S, Greenwood RJ, Oliver DL. Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst Rev. 2006; 4:CD003299.
3. Endo F, Matsuura T, Yanagita K et al. Clinical manifestations of inborn errors of the urea cycle and related metabolic disorders during childhood. J Nutr. 2004; 134(suppl 6):1605S-1609S. (Pubitemid 38720747)
4. Alqahtani S, Federico P, Myers RP. A case of valproate-induced hyperammonemic encephalopathy: look beyond the liver. CMAJ. 2007; 177:568-569 (Pubitemid 47437052)
5. National Urea Cycle Disorders Foundation. What is a urea cycle disorder? www.nucdf.org/ucd.htm (accessed 2008 Jul 21).
6. Weiner DL. Pediatrics, inborn errors of metabolism. www.emedicine.com/ emerg/topic768.htm (accessed 2008 Jul 21).
7. Yee JL, Wong D, Ormiston TM. Encephalopathy and hyperammonemia associated with valproic acid. J Pharm Technol. 2005; 21:348-350 (Pubitemid 41784983)
8. Carr RB, Shrewsbury K. Hyperammonemia due to valproic acid in the psychiatric setting. Am J Psychiatry. 2007; 164:1020-7. (Pubitemid 47121390)
9. Verrotti A, Trotta D, Morgese G et al. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis. 2002; 17:367-373
10. Williams CA, Tiefenbac S, McReynolds JW. Valproic acid-induced hyperammonemia in mentally retarded adults. Neurology. 1984; 34:550-553
11. Clay AS, Hainline BE. Hyperammonemia in the ICU. Chest. 2007; 132:1368-1378
12. Ambrosetto G, Riva R, Baruzzi A. Hyperammonemia in asterixis induced by carbamazepine: two case reports. Acta Neurol Scand. 1984; 69:186-189 (Pubitemid 14155923)
13. Rivelli M, El-Mallakh RS, Nelson WH. Carbamazepine-associated asterixis and hyperammonemia. Am J Psychiatry. 1988; 145:269-270
14. Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand. 2008; 118:281-290
15. Hamer H, Knake S, Schomburg U et al. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology. 2000; 54:230-232 (Pubitemid 30038768)
16. Raja M, Azzoni A. Valproate-induced hyperammonaemia. J Clin Psychopharmacol. 2002; 22:631-633 Letter.
17. Wadzinski J, Franks R, Roane D et al. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med. 2007; 20:499-502.
18. Laub MC, Paetzke-Brunner I, Jaeger G. Serum carnitine during valproic acid therapy. Epilepsia. 1986; 27:559-562 (Pubitemid 16026053)
19. Ohtani Y, Endo F, Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr. 1982; 101:782-785
20. Sease JM, Timm EG, Stragand JJ. Portal hypertension and cirrhosis. In: Dipiro JT, Talbert RL, Yee GC et al., eds. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York: McGraw Hill; 2008: 645.
21. Brown JR. Cirrhosis. In: Helms RA, Quan DJ, Herfindal ET et al., eds. Textbook of therapeutics: drug and disease management. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2006:1358.
22. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-245
23. Klasco RK, ed. Drugdex system. Greenwood Village, CO: Thomson Healthcare. Updated periodically.